Product overview

Name VX 702
Purity >98%
Description Potent, selective ATP-competitive p38 MAPK inhibitor
Write Your Own Review
You're reviewing:VX 702
Rate this item:

Biological Data

Biological description Potent and selective ATP-competitive p38 MAPK inhibitor (Kd values are 3.7 and 17 nM for p38α and p38β respectively). Also inhibits production of IL-6, IL-1β and TNFα (IC50 values are 59, 122 and 99 ng/ml respectively). Exhibits no activity for ERKs and JNKs Displays anti-inflammatory properties.

Solubility & Handling

Storage instructions +4°C
Solubility overview Soluble in DMSO (100mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >98%
Chemical name 6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxa mide
Molecular Weight 404.32
Molecular Formula C19H12F4N4O2
CAS Number 745833-23-2
PubChem identifier 10341154
SMILES NC(N(C3=C(F)C=CC=C3F)C1=CC=C(C(N)=O)C(C2=C(F)C=C(F)C=C2)=N1)=O
InChiKey FYSRKRZDBHOFAY-UHFFFAOYSA-N

References for VX 702

References are publications that support the biological activity of the product
  • An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion.

    Skripchenko A et al (2013) PLoS One 8(8) : e70732.
  • Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

    Goldstein DM et al (2010) J Med Chem 53(6) : 2345-53.
  • Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.

    Ding C (2006) Curr Opin Investig Drugs 7(11) : 1020-5.

3 Item(s)